Clinical Research Sites for the MACS/WIHS Combined Cohort Study (MACS/WIHS-CCS) - Baltimore/Wash DC Center

摘要 基金年2023 OAR战略基金被要求进行高通量蛋白质组学 测量以研究MWCCS中心功能不全的蛋白质特征。 既往在完成基线超声心动图检查的受试者中采集的血液标本 在MACS访视67-71（n=1195）和WIHS访视44-50（n=1655）中， 蛋白质组学，以允许发现蛋白质标记物。MACS和WIHS中的基因型数据 将利用蛋白质数量性状进行孟德尔随机化分析 基因座，允许因果推断和选择药物治疗的蛋白质靶点。这 一份补充材料将支持与以下NIH高度优先事项相对应的HIV/AIDS研究 艾滋病指定专题：（1）艾滋病毒相关的合并症;（2）涉及艾滋病的交叉领域 临床转化研究、心血管疾病、蛋白质组学、多组学和健康 （3）对下一代艾滋病毒研究人员进行组学培训， 共病研究。

Abstract Fund Year 2023 OAR Strategic Funds are requested to perform high-throughput proteomic measurements to investigate the protein signatures of cardiac dysfunction in MWCCS. Previously collected blood specimens in participants who completed baseline echocardiography in MACS Visits 67-71 (n=1195) and WIHS Visits 44-50 (n=1655) will be used to measure proteomics in order to permit discovery of protein markers. Genotypic data in MACS and WIHS will be leveraged to conduct Mendelian randomization analysis using protein quantitative trait loci, allowing causal inference and selection of protein targets for pharmacotherapy. This supplement will support HIV/AIDS research corresponding to the following NIH high-priority AIDS-designated topics: (1) HIV-associated comorbidities; (2) cross-cutting areas involving clinical translational research, cardiovascular disease, proteomics, multi-omics, and health disparities; and (3) training of the next generation of HIV investigators in omics and comorbidities research.